Hepatitis B Reactivation risk in patients with rheumatologic diseases under biologic treatment
Acta Medica Mediterranea, cilt.37, sa.3, ss.1529-1533, 2021 (SCI-Expanded, Scopus)
- Yayın Türü: Makale / Tam Makale
- Cilt numarası: 37 Sayı: 3
- Basım Tarihi: 2021
- Doi Numarası: 10.19193/0393-6384_2021_3_244
- Dergi Adı: Acta Medica Mediterranea
- Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus, EMBASE
- Sayfa Sayıları: ss.1529-1533
- Anahtar Kelimeler: cytokine inhibitors, hepatitis B reactivation, rheumatology, resolved HBV, rituximab, TNF a inhibitors
- Sağlık Bilimleri Üniversitesi Adresli: Evet
Özet
Introduction: Hepatitis B virus reactivation (HBVr) is a clinical entity that can occur due to the use of immunosuppressive medications and caus es serious complications that can threaten survival. In this study, we aime d to investigate the effects of the biological agents used in rheumatology on HBVr in a large patient population. Materials and methods: Patients with rheumatolog ic diseases who were on biological treatment were analyzed according to hepatitis B virus (HBV) serology. Patients with resolved HBV and inactive chronic HBV were included in the study. Prophylaxis status, HBVr and hepatic flare were recorded. Results: 749 patients were screened by medical records. 106 (14.2%) patients were in the resolved HBV group and 15 (2%) patients were inactive HBV carrier. Prophylaxis was not administere d to 74 (69.8 %) patients in the resolved HBV group and 4 (26.7%) patients in the inactive chronic HBV group. None of t he patients demonstrate d HBVr. Conclusion: We suggest that long-term prophylactic oral antiviral treatment can be avoide d by the close follow-up of patients who were on tumour necrosis factor α (TNF α) or cytokine inhibitors due to low HBVr risk. On the other hand, patients receiving rituximab must be more carefully evaluated to prevent patients from not receiving antiviral prophylaxis.